IGF::OT::IGF R&D- DOSE DE-ESCALATION TRIAL TO IDENTIFY THE LOWEST COMMERCIALLY AVAILABLE DOSE OF LINACLOTIDE THAT MAINTAINS BIOACTIVITY IN RECTAL MUCOSA

Mayo Clinic Rochester, Rochester MN

Investigators

Abstract

The proposed Phase I dose ranging clinical trial is designed to identify the lowest commercially available dose of linaclotide that achieves a statistically significant elevation of rectal cGMP after seven (7) days of administration.